Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Gain Therapeutics, Inc.

< Previous 1 2 Next >
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics To Participate in Upcoming Investor Conferences
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics To Present At Biotech Showcase 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate at Upcoming Investor Conferences
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.